TY - JOUR
T1 - Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue
AU - for the Undiagnosed Diseases Network
AU - Sharma, Richa
AU - Sahoo, Sushree S.
AU - Honda, Masayoshi
AU - Granger, Sophie L.
AU - Goodings, Charnise
AU - Sanchez, Louis
AU - Künstner, Axel
AU - Busch, Hauke
AU - Beier, Fabian
AU - Pruett-Miller, Shondra M.
AU - Valentine, Marcus B.
AU - Fernandez, Alfonso G.
AU - Chang, Ti Cheng
AU - Géli, Vincent
AU - Churikov, Dmitri
AU - Hirschi, Sandrine
AU - Pastor, Victor B.
AU - Boerries, Melanie
AU - Lauten, Melchior
AU - Kelaidi, Charikleia
AU - Cooper, Megan A.
AU - Nicholas, Sarah
AU - Rosenfeld, Jill A.
AU - Polychronopoulou, Sophia
AU - Kannengiesser, Caroline
AU - Saintomé, Carole
AU - Niemeyer, Charlotte M.
AU - Revy, Patrick
AU - Wold, Marc S.
AU - Spies, Maria
AU - Erlacher, Miriam
AU - Coulon, Stéphane
AU - Wlodarski, Marcin W.
N1 - Funding Information:
This work was supported by grants from the ERAPERMED GATA2-HuMo 2018-123, Deutsche Krebshilfe Max Eder Grant 109005, Fritz-Thyssen Foundation 10.17.1.026MN, and St Jude American Lebanese Syrian Associated Charities (M.W.W.), José Carreras Leukämie-Stiftung (V.P.L.), BMBF MyPred 01GM1911A (C.M.N., M.W.W., and M.E.). Research reported in the manuscript was supported by the National Institutes of Health (NIH) Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award U01HG007709. The St Jude Cancer Center Core Cytogenetics Laboratory is supported by the NIH, National Cancer Institute (P30 CA21765-41), and American Lebanese Syrian Associated Charities. M.S. is supported by the NIH, National Institute of General Medical Sciences (R35GM131704), and the National Cancer Institute (P30CA086862). C.K., C.S., P.R., and S.C. are supported by the Agence Nationale de la Recherche (ANR-20-CE12-0012TeloRPA). H.B. and A.K. are supported by Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy (EXC 22167-390884018). The P3 exome study was supported by a grant from the Chancellerie des Universités de Paris (legs Poix). The laboratories of V.G. and P.R. are supported by the “Ligue Nationale Contre le Cancer” (Equipe Laboratoryélisée). P.R. is a scientist from Centre National de la Recherche Scientifique. S.C. is supported by Project Fondation ARC, Projet Emergence-Cancéropôle PACA. This work was generated within the European Reference Network for Paediatric Cancer (PAEDCAN). The authors acknowledge the contribution of the Center of Inborn and Acquired Blood Diseases at the Freiburg Center for Rare Diseases, and the Hilda Biobank at the Department of Pediatrics and Adolescent Medicine, Freiburg, Germany. M.B. is supported by the Deutsche Forschungsgemeinschaft (DFG) - CRC 1479 (Project ID: 441891347-S1), CRC 1160 (Project Z02), CRC1453 (Project ID 431984000-S1) and T RR167 (Project Z01), the German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B).
Funding Information:
The authors thank the patients for participation. The authors also acknowledge their collaborators: Dirk Lebrecht, Marco Teller, Ali-Riza Kaya, Wilfried Truckenmüller, Maria Siskou-Zwecker, and Axel Gebert (Freiburg, Germany) for laboratory assistance and data management; Loizos Petrikkos and Kondylia Antoniadi (Athens, Greece) for patient management; Ibrahima Ba for technical assistance and Bruno Crestani for helpful discussions (Paris, France); Lindsay Burrage for exome analysis and Filiz Seeborg for P4 referral; Yawei Hui, Shibiao Wan, Yiping Fan, and Gang Wu (St Jude Center for Applied Bioinformatics); OMICS computing cluster (University of Lübeck); Emmanuelle Olivier and Patrick Nitschké (Imagine Institute/Université de Paris) for bioinformatics support; Robert Durruthy-Durruthy (Mission Bio) for support on single-cell DNA sequencing analysis; Amabel Orogo (Illumina) and Jordan Sheetz (Bio-Rad Laboratories) for technical support; Mihaela Onciu (Department of Pathology, St Jude Children's Research Hospital) for iPSC-derived erythroid and myeloid cytology review; Aaron Taylor (St Jude Center of Imaging) for imaging consultation; Sunita Dsouza, Maria Lillo Osuna, and Min-Joon Han (St Jude Children's Research Hospital) for iPSC technical assistance; Virginia Valentine and Julia Wilbourne (St Jude Cytogenetics Core); and Mitchell Weiss and John Crispino for helpful discussions. This work was supported by grants from the ERAPERMED GATA2-HuMo 2018-123, Deutsche Krebshilfe Max Eder Grant 109005, Fritz-Thyssen Foundation 10.17.1.026MN, and St Jude American Lebanese Syrian Associated Charities (M.W.W.), José Carreras Leukämie-Stiftung (V.P.L.), BMBF MyPred 01GM1911A (C.M.N. M.W.W. and M.E.). Research reported in the manuscript was supported by the National Institutes of Health (NIH) Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award U01HG007709. The St Jude Cancer Center Core Cytogenetics Laboratory is supported by the NIH, National Cancer Institute (P30 CA21765-41), and American Lebanese Syrian Associated Charities. M.S. is supported by the NIH, National Institute of General Medical Sciences (R35GM131704), and the National Cancer Institute (P30CA086862). C.K. C.S. P.R. and S.C. are supported by the Agence Nationale de la Recherche (ANR-20-CE12-0012TeloRPA). H.B. and A.K. are supported by Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy (EXC 22167-390884018). The P3 exome study was supported by a grant from the Chancellerie des Universités de Paris (legs Poix). The laboratories of V.G. and P.R. are supported by the “Ligue Nationale Contre le Cancer” (Equipe Laboratoryélisée). P.R. is a scientist from Centre National de la Recherche Scientifique. S.C. is supported by Project Fondation ARC, Projet Emergence-Cancéropôle PACA. This work was generated within the European Reference Network for Paediatric Cancer (PAEDCAN). The authors acknowledge the contribution of the Center of Inborn and Acquired Blood Diseases at the Freiburg Center for Rare Diseases, and the Hilda Biobank at the Department of Pediatrics and Adolescent Medicine, Freiburg, Germany. M.B. is supported by the Deutsche Forschungsgemeinschaft (DFG) - CRC 1479 (Project ID: 441891347-S1), CRC 1160 (Project Z02), CRC1453 (Project ID 431984000-S1) and T RR167 (Project Z01), the German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/2/17
Y1 - 2022/2/17
N2 - Human telomere biology disorders (TBD)/short telomere syndromes (STS) are heterogeneous disorders caused by inherited loss-of-function mutations in telomere-associated genes. Here, we identify 3 germline heterozygous missense variants in the RPA1 gene in 4 unrelated probands presenting with short telomeres and varying clinical features of TBD/STS, including bone marrow failure, myelodysplastic syndrome, T- and B-cell lymphopenia, pulmonary fibrosis, or skin manifestations. All variants cluster to DNA-binding domain A of RPA1 protein. RPA1 is a single-strand DNA-binding protein required for DNA replication and repair and involved in telomere maintenance. We showed that RPA1E240K and RPA1V227A proteins exhibit increased binding to single-strand and telomeric DNA, implying a gain in DNA-binding function, whereas RPA1T270A has binding properties similar to wild-type protein. To study the mutational effect in a cellular system, CRISPR/Cas9 was used to knock-in the RPA1E240K mutation into healthy inducible pluripotent stem cells. This resulted in severe telomere shortening and impaired hematopoietic differentiation. Furthermore, in patients with RPA1E240K, we discovered somatic genetic rescue in hematopoietic cells due to an acquired truncating cis RPA1 mutation or a uniparental isodisomy 17p with loss of mutant allele, coinciding with stabilized blood counts. Using single-cell sequencing, the 2 somatic genetic rescue events were proven to be independently acquired in hematopoietic stem cells. In summary, we describe the first human disease caused by germline RPA1 variants in individuals with TBD/STS.
AB - Human telomere biology disorders (TBD)/short telomere syndromes (STS) are heterogeneous disorders caused by inherited loss-of-function mutations in telomere-associated genes. Here, we identify 3 germline heterozygous missense variants in the RPA1 gene in 4 unrelated probands presenting with short telomeres and varying clinical features of TBD/STS, including bone marrow failure, myelodysplastic syndrome, T- and B-cell lymphopenia, pulmonary fibrosis, or skin manifestations. All variants cluster to DNA-binding domain A of RPA1 protein. RPA1 is a single-strand DNA-binding protein required for DNA replication and repair and involved in telomere maintenance. We showed that RPA1E240K and RPA1V227A proteins exhibit increased binding to single-strand and telomeric DNA, implying a gain in DNA-binding function, whereas RPA1T270A has binding properties similar to wild-type protein. To study the mutational effect in a cellular system, CRISPR/Cas9 was used to knock-in the RPA1E240K mutation into healthy inducible pluripotent stem cells. This resulted in severe telomere shortening and impaired hematopoietic differentiation. Furthermore, in patients with RPA1E240K, we discovered somatic genetic rescue in hematopoietic cells due to an acquired truncating cis RPA1 mutation or a uniparental isodisomy 17p with loss of mutant allele, coinciding with stabilized blood counts. Using single-cell sequencing, the 2 somatic genetic rescue events were proven to be independently acquired in hematopoietic stem cells. In summary, we describe the first human disease caused by germline RPA1 variants in individuals with TBD/STS.
UR - http://www.scopus.com/inward/record.url?scp=85124601326&partnerID=8YFLogxK
U2 - 10.1182/blood.2021011980
DO - 10.1182/blood.2021011980
M3 - Article
C2 - 34767620
AN - SCOPUS:85124601326
SN - 0006-4971
VL - 139
SP - 1039
EP - 1051
JO - Blood
JF - Blood
IS - 7
ER -